Turning Point Therapeutics Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
This Turning Point Therapeutics Company BD Opportunity Scan Report was built with PatSnap Life Sciences MCP workflows. Company & Deal Intelligence MCP connects the organization pipeline, transaction precedents and financial-report signals; Current Awareness MCP adds recent-event context. The output is a partnering shortlist with owner, stage, evidence package, IP risk, deal precedent and outreach rationale. Explore the MCP servers used in this report.
Decision date: 21 July 2026. This is a screening memorandum for business-development prioritization, not legal, patent, medical or investment advice. “Not returned” means the searched MCP result did not supply the field and should not be read as evidence of absence.
Executive BD thesis
Turning Point Therapeutics presents a practical BD-screening case because its returned pipeline contains 16 records and the deal search returned 3 transaction records. The lead returned asset is Repotrectinib, associated with ROS1 x TrkA x TrkB x TrkC and KRAS G12D mutation Solid Tumors, KRAS mutation-related tumors, Anaplastic Large-Cell Lymphoma, at Phase 2. The immediate objective is not to price a transaction; it is to identify where a focused outreach can unlock regional development, indication expansion, platform access, combination strategy, manufacturing leverage or non-dilutive capital.
The scan prioritizes assets with a named development owner and a traceable stage, then applies a conservative IP screen. A high-quality first meeting should ask for the current clinical/regulatory package, ownership chain, third-party licenses, patent-family schedule, CMC readiness and the specific rights the company is prepared to discuss.
Partnering shortlist
| Priority | Asset / workstream | Owner | Stage | Evidence package | IP risk screen | Deal precedent | Outreach rationale |
|---|---|---|---|---|---|---|---|
| 1 | Repotrectinib | Turning Point Therapeutics, Inc. | Phase 2 | Pipeline record: ROS1 x TrkA x TrkB x TrkC; KRAS G12D mutation Solid Tumors, KRAS mutation-related tumors, Anaplastic Large-Cell Lymphoma. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | Turning Point Therapeutics and MD Anderson Announce Strategic Alliance to Advance Precision Cancer Therapies | Phase 2 asset with ROS1 x TrkA x TrkB x TrkC exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
| 2 | LM-302 | Turning Point Therapeutics, Inc. | Phase 2 | Pipeline record: CLDN18.2 x Tubulin; Gastrointestinal Neoplasms, Advanced Malignant Solid Neoplasm. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | Bristol Myers Squibb to Acquire Turning Point Therapeutics, a Leading Precision Oncology Company | Phase 2 asset with CLDN18.2 x Tubulin exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
| 3 | Elzovantinib | Turning Point Therapeutics, Inc. | Phase 2 | Pipeline record: CSF-1R x SRC family x c-Met; Advanced Malignant Solid Neoplasm, Gastroesophageal junction adenocarcinoma, Gastrooesophageal junction cancer. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | Turning Point Therapeutics and Zai Lab Announce Exclusive License Agreement for Repotrectinib in Greater China | Phase 2 asset with CSF-1R x SRC family x c-Met exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
| 4 | TPX-02226 | Turning Point Therapeutics, Inc. | Preclinical | Pipeline record: CSF-1R x SRC x c-Met; Neoplasms. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | Turning Point Therapeutics and MD Anderson Announce Strategic Alliance to Advance Precision Cancer Therapies | Preclinical asset with CSF-1R x SRC x c-Met exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
| 5 | THTT analogue 28(NED University of Engineering and Technology) | Turning Point Therapeutics, Inc. | Preclinical | Pipeline record: COX-1; Gastrointestinal motility disorder. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | Bristol Myers Squibb to Acquire Turning Point Therapeutics, a Leading Precision Oncology Company | Preclinical asset with COX-1 exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
Shortlist interpretation. The top row should receive the fastest outreach, subject to confirmation that the returned owner and development stage remain current. Rows two through five are option-value workstreams: they can support a regional license, co-development, research collaboration, asset carve-out or structured option if the evidence package is sufficiently differentiated.
Pipeline and evidence-package readout
The organization pipeline fetch anchors asset identity, target, indication and development stage. Those fields should be reconciled against the sponsor’s current presentation, trial registry, regulatory correspondence and data-room index. For each shortlisted asset, request protocol history, enrollment and discontinuation data, endpoint definitions, biomarker strategy, safety narratives, manufacturing comparability and the latest investigator or regulator feedback.
Evidence quality is strongest when asset identity, stage, owner and indication are mutually consistent across sources. A mismatch is itself a BD signal: it may reflect a recent transfer, dormant program, territory split, combination strategy or portfolio reprioritization. Any mismatch should be resolved before valuation or term-sheet design.
Deal precedents and structure signals
| Date | Transaction | Status | Disclosed economics |
|---|---|---|---|
| 2022-06-24 | Turning Point Therapeutics and MD Anderson Announce Strategic Alliance to Advance Precision Cancer Therapies | Active | disclosed: false |
| 2022-06-03 | Bristol Myers Squibb to Acquire Turning Point Therapeutics, a Leading Precision Oncology Company | Completed | total_amount: 4100; disclosed: false |
| 2020-07-07 | Turning Point Therapeutics and Zai Lab Announce Exclusive License Agreement for Repotrectinib in Greater China | Active | upfront_payment: 25; milestone_payment: 151; total_amount: 176; disclosed: true |
The most relevant returned precedent is: Turning Point Therapeutics and MD Anderson Announce Strategic Alliance to Advance Precision Cancer Therapies (2022-06-24). Precedents should guide structure rather than mechanically determine price. Normalize for development stage, territory, modality, included indications, opt-in rights, cost sharing, manufacturing obligations, royalties, milestones and change-of-control provisions. Where economics are undisclosed, the precedent still informs counterparties, strategic intent and preferred transaction form.
Financial capacity and partnering pressure
- Turning Point Therapeutics, Inc. - 2021 Quarterly report: Turning Point Therapeutics, Inc. - 2021 Quarterly report Liquidity and Capital Resources At March 31, 2021, we had $1,114.8 million of cash, cash equivalents and marketable securities compared to $1,122.5 million at December 31, 2020. Based on our current and anticipated level of operations, we believe that our cash, cash equivalents and marketable securities as of March 31, 2021, will be sufficient to fund current operations for at least one year from the date that this Quarterly Report is filed with the SEC. Since inception, our operations have been financed primarily through the sale of common stock and convertible preferred stock. Through March 31, 2021, we received net proceeds of approximately $1,321.1 million from the issuance of common stock and convertible preferred stock and thro
- Turning Point Therapeutics, Inc. - 2020 Annual report: Turning Point Therapeutics, Inc. - 2020 Annual report RISK FACTORS Turning Point Therapeutics, Inc.'s Statement of Cash Flows Data highlights the company's cash movements over three consecutive years. In 2020, the company utilized $82,793 in net cash for operating activities, a figure that increased from $57,757 in 2019, and more than tripled from $23,533 in 2018. Conversely, net cash used in investing activities showed significant variability, with $210,032 used in 2020, substantially less than the $361,079 used in 2019, but markedly more than the negligible $302 used in 2018. Meanwhile, financing activities generated considerable cash, with $798,738 provided in 2020, surpassing the $365,995 in 2019, and significantly exceeding the $79,831 in 2018, indicating a notable escalation in finan
Financial signals influence timing and leverage. Cash runway, operating burn, committed trial spend, debt covenants, shelf capacity and recent financings determine whether Turning Point Therapeutics is more likely to pursue a broad license, regional partnership, cost-sharing collaboration, royalty financing or asset-level option. Figures returned from filings should be rechecked in the latest report before any negotiation.
Recent events and outreach timing
- No company-specific recent-news passage was returned. Confirm the latest clinical, regulatory, financing and leadership events directly with management.
Recent clinical, regulatory, financing, leadership and portfolio events can create a narrow outreach window. The BD team should map each event to a decision owner, an asset-level question and a proposed structure. Avoid generic “partnership interest” messages; lead with the specific program, territory, capability gap and evidence package that the prospective partner can improve.
IP and diligence risk screen
The default IP flag is medium until verified. Review composition-of-matter and sequence claims, method-of-use coverage, formulation and delivery patents, manufacturing know-how, platform licenses, university or government rights, prosecution status, patent-term adjustment/extension, oppositions, litigation, inventorship and freedom to operate. For biologics, cell/gene therapies and platform technologies, background IP and improvement-right provisions can be as important as the asset patents.
Commercial diligence should test addressable population, diagnosis and referral pathway, standard of care, competitor readouts, endpoint sensitivity, payer evidence needs, launch infrastructure and territory-specific regulatory requirements. The value of an asset is a function of the complete evidence package and executable rights—not development stage alone.
Recommended outreach sequence
- Contact the asset-level BD owner with a one-page rationale linked to the lead program and proposed territory or capability contribution.
- Request a non-confidential package covering current stage, dataset maturity, ownership, patent schedule, CMC status and partnering perimeter.
- Benchmark the returned precedents using stage-, modality- and territory-adjusted structures.
- Advance only programs with a coherent owner, evidence package, IP path and decision timeline into confidential diligence.
- Set explicit stop/go gates for data quality, freedom to operate, financing capacity and strategic fit.
Bottom line
Turning Point Therapeutics merits targeted BD outreach where the returned pipeline and evidence package align with a partner’s geography, development capability or commercial infrastructure. The recommended next action is to validate Repotrectinib, confirm rights availability and test a structure calibrated to the company’s financial position and precedent set. The shortlist is designed to turn fragmented intelligence into an actionable owner-by-owner outreach plan.
Explore PatSnap Open Platform MCP Servers and build your next biopharma BD workflow.
